Prostate Cancer Clinical Trial
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Summary
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Eligibility Criteria
Inclusion Criteria:
At least 18 years of age.
Signed informed consent.
Untreated, histologically confirmed adenocarcinoma of the prostate.
High-risk or greater PC defined by National Comprehensive Cancer Network Guidelines Version 1.202327 (clinical stage ≥T3a, or Grade Group ≥4, or PSA >20 ng/mL).
Patients electing to undergo RP with PLND.
Exclusion Criteria:
Administration of any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1.
Known or expected hypersensitivity to 64Cu-SAR-bisPSMA or any of its components.
Patients with known predominant small cell or neuroendocrine PC.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Glenview Illinois, 60026, United States More Info
Contact
Omaha Nebraska, 68130, United States More Info
Principal Investigator
Myrtle Beach South Carolina, 29572, United States More Info
Principal Investigator
Dallas Texas, 75231, United States More Info
Contact
How clear is this clinincal trial information?
